Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

• Denali Therapeutics shares climbed in afternoon trading, gaining ground while the broader biotech sector remained flat.• Attention intensified following the FDA’s decision to halt Regenxbio’s rare-disease gene therapy trials.• Investors are now zeroed in on Denali’s FDA timeline for its Hunter syndrome treatment and the data update expected in early February.

Biotechnology · NASDAQ:DNLI · NASDAQ:RGNX · Pharmaceutical Industry · Stock Market
Top Pre‑Market Losers Today (December 10, 2025): AFJK, CBRL, DNLI & AEG Lead Early Declines Before the Bell

Top Pre‑Market Losers Today (December 10, 2025): AFJK, CBRL, DNLI & AEG Lead Early Declines Before the Bell

U.S. stock futures are pretty calm this morning as traders wait for a pivotal Federal Reserve rate decision later today – but under the surface, pre‑market trading is anything but quiet. A handful of thinly traded micro‑caps are collapsing after spectacular rallies, while recognizable names like Cracker Barrel, Denali Therapeutics, Aegon and Biogen are under pressure on fresh news and analyst calls. Nasdaq+3StockAnalysis+3Investing.com+3
10 December 2025
····
Follow on Google News
Add as preferred source Open in Google News

US Stock Market Today Updates

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 Strong Buy

NVIDIA

94/100
#2 Strong Buy

Meta Platforms

89/100
#3 Buy

Alphabet

87/100
#4 Buy

Amazon

84/100
#5 Selective Buy

Microsoft

82/100
View full portfolio
Editorial model selection. Not personalised advice.